GI
CORT icon

Gradient Investments’s Corcept Therapeutics CORT Stock Holding History

Gradient Investments’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-49
Closed -$995 – 1540
2022
Q4 		$995 Buy
+49
New +$1.23K ﹤0.01% 1197

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Gradient Investments's CORT Position: Q1 2023 in Review

Gradient Investments sold out of Corcept Therapeutics (CORT) in Q1 2023, closing a stake of 49 shares — an estimated $995 sold.

Gradient Investments first reported a position in CORT in Q4 2022 and held it in 1 quarter. The position peaked at $995 in Q4 2022. 232 funds tracked by Wall St. Rank hold CORT as of Q1 2023.

  • Gradient Investments reported no remaining Corcept Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Gradient Investments sold 49 Corcept Therapeutics shares in Q1 2023, an estimated $995.
  • Gradient Investments first reported a position in Corcept Therapeutics in Q4 2022 and held it in 1 quarter.
  • Gradient Investments's Corcept Therapeutics position peaked at $995 in Q4 2022.
  • 232 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2023.

Based on Gradient Investments's 13F filing for Q1 2023, filed 17 Apr 2023.